![pills_rapid_release_pills_By_Katy_Warner_from_Orlando_FL_USA_[CC-BY-SA-3.0_(http_creativecommons.org_licenses_by-sa_3.0)]_via_Wikimedia_Commons pills_rapid_release_pills_By_Katy_Warner_from_Orlando_FL_USA_[CC-BY-SA-3.0_(http_creativecommons.org_licenses_by-sa_3.0)]_via_Wikimedia_Commons](../news/img/healthcare/pills_rapid_release_pills_By_Katy_Warner_from_Orlando_FL_USA_[CC-BY-SA-3.0_(http_creativecommons.org_licenses_by-sa_3.0)]_via_Wikimedia_Commons.jpg)
Veru Inc reported disastrous Sep 30 2022 report, where Revenue faded by -83.455 % to $
2.59 millions and net deficit per share has expanded to $-0.51, from the corresponding reporting season a year before.
from the previous reporting season from $-0.28 per share, Revenue Tumbled sequentially by -73.041 % from $9.60 millions.
For the fiscal interval ending September 30 2022 Veru Inc realized net loss of $-41.023 million, higher than $-4.294 million a year ago.
Veru Inc announced net deficit of $-83.78 millions and Revenues of $39.35 millions for the financial year 2022.
Major Pharmaceutical Preparations company also mentioned that, its eps were at $-1.05 in proportion to $0.09 in the prior financial year, while Revenue Tumbled by -35.76 % from $61.26 millions a year before.
Veru Inc is expected to report next financial earnings on February 08, 2023.